Taiwan Exosome Co., Ltd. was established in 2021, dedicated to the horizontal and vertical development of novel drugs using human, animal, and plant exosomes. The company conducts in-depth scientific research and development in exosome industry technology, utilizing the most professional knowledge, equipment, and advanced technology as the foundation. It focuses on developing treatments for difficult-to-treat diseases, including autoimmune diseases and sarcopenia. Taiwan Exosome also aims to establish a "Pharmaceutical-Grade Exosome Industry Technology Platform," which includes modules for exosome separation, purification, identification, and mass production technology, making it a leader across the upstream, midstream, and downstream regenerative medical industry chain.